OBI Pharma and TegMine Therapeutics have entered into an exclusive global licensing agreement for glycan-targeted ADCs.
Taipei, Taiwan, January 12, 2026 - (JCN Newswire) - OBI Pharma (4174.TWO) announced that it has entered into a commercial licensing agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharmaceutical company focused on the development of antibodies targeting cancer-related glycans and glycoproteins, for glycan-targeted ADCs.
Dr. Heidi Wang, CEO of OBI Pharma, stated:
"This strategic partnership leverages the complementary strengths of both organizations. It will not only support the advancement of OBI's ADC product development but also expand opportunities for strategic partnerships utilizing innovative ADC technologies such as GlycOBI. We look forward to closely collaborating with TegMine to further develop this novel ADC, which has the potential to benefit patients with urgent medical needs."

Inquiry about this news
Contact Us Online




